The launch of the Pipeline therapies, increasing EPI prevalence shall fuel the Exocrine pancreatic insufficiency market size estimated to be approximately USD 1,695.26 Million in 2017.
A loss of acinar pancreatic cells that causes insufficient production of pancreatic enzymes in the duodenum results in Exocrine pancreatic insufficiency (EPI). It manifests as a malabsorption syndrome and a major burden on global healthcare due to high morbidity and mortality rates.
EPI is a consequence of several different indications, which share the common pathophysiologic end result of inadequate enzyme digestion, including Celiac Disease, Cystic Fibrosis, Ul...
